Last updated: November 5, 2026
Felbatol, the brand name for felbamate, is a mature, low-volume antiseizure medicine used mainly when other treatments fail. Its commercial value is constrained by severe safety warnings, limited prescribing, generic competition, and the absence of meaningful exclusivity. The product remains clinically relevant for refractory epilepsy, particularly Lennox-Gastaut syndrome, but it is not a major growth asset.
Felbatol has no biosimilar exposure because felbamate is a small-molecule drug. The principal commercial risks are generic price competition, manufacturing continuity, restricted prescribing, and demand concentration among specialist epilepsy patients. Public sources do not report standalone Felbatol revenue, making precise product-level revenue estimates unavailable.
What is Felbatol approved to treat?
Felbatol is an oral formulation of felbamate, an antiseizure active ingredient. The FDA approved Felbatol in 1993 for:
- Partial seizures, with or without generalization, in adults.
- Partial and generalized seizures associated with Lennox-Gastaut syndrome in children.
The FDA labeling limits use because felbamate has been associated with aplastic anemia and acute liver failure. The product carries a boxed warning and requires risk-benefit assessment, informed consent, and monitoring of blood counts and liver function.[1]
What formulations and strengths are available?
Felbatol has historically been marketed as:
- 400 mg and 600 mg tablets.
- An oral suspension, commonly labeled at 600 mg/5 mL.
The oral suspension is commercially important because Lennox-Gastaut patients may require liquid administration. Formulation substitution is not always operationally neutral: tablet availability, suspension availability, excipient tolerability, and pharmacy supply can affect continuity of therapy.
Felbamate is also distributed under generic labeling. Product availability can vary by manufacturer, wholesaler inventory, and pharmacy contracting.
When does Felbatol lose exclusivity?
Felbatol lost meaningful market exclusivity years ago. The 1993 approval date places the product well beyond the statutory period for new chemical entity exclusivity and any original patent term that could have supported current branded protection.
What is the Orange Book status of Felbatol?
Felbatol is not commercially protected by a current Orange Book patent estate comparable to newer branded antiepileptic drugs. The principal competitive structure is generic substitution rather than patent litigation.
A current Orange Book review is still necessary for transaction-specific diligence because listings can change by product, dosage form, and applicant. The commercially relevant conclusion is that no active Felbatol patent barrier is widely recognized as a material impediment to generic competition.
How many patents cover Felbatol?
No meaningful active patent cluster is associated with the mature felbamate product. Historical composition-of-matter and formulation rights, if any, have expired or no longer determine market access.
The absence of patent protection does not eliminate supply risk. For a low-volume medicine, the more important barriers can be:
- Limited manufacturing economics.
- Raw-material sourcing.
- Quality-system requirements.
- Inventory carrying costs.
- Low expected return from additional suppliers.
- Regulatory costs associated with maintaining multiple dosage forms.
What is the FDA regulatory status of Felbatol?
Felbatol remains an FDA-approved prescription antiseizure medicine. Its regulatory profile is defined by a serious boxed warning rather than by pending approval activity.
| Regulatory factor |
Felbatol status |
| Active ingredient |
Felbamate |
| Drug class |
Antiseizure medication |
| FDA approval |
1993 |
| Dosage forms |
Tablets and oral suspension |
| Main indications |
Partial seizures; Lennox-Gastaut syndrome |
| Boxed warning |
Aplastic anemia and hepatic failure |
| Prescription status |
Prescription-only |
| Biosimilar pathway |
Not applicable |
| Current commercial model |
Brand and generic supply |
| Patent-driven exclusivity |
No material current barrier |
The boxed warning narrows the treatable population and increases the operational burden on prescribers. The FDA labeling recommends baseline and periodic hematologic and hepatic monitoring, although the label states that monitoring cannot reliably prevent aplastic anemia.[1]
What generic entry risks exist for Felbatol?
Generic entry is already established, so the relevant risk is continued generic substitution rather than a future first generic launch.
Which companies are challenging Felbatol?
Publicly visible market activity does not indicate a major current Paragraph IV campaign against Felbatol. Because the product is already genericized and patent protection is not a central commercial issue, Paragraph IV litigation is unlikely to drive the market.
The competitive field is more likely to include generic abbreviated new drug application holders, contract manufacturers, wholesalers, and pharmacy suppliers than branded challengers.
What does generic competition do to Felbatol pricing?
Generic competition generally compresses prices, particularly for tablets with multiple approved suppliers. The effect can be less predictable for the oral suspension because:
- Fewer suppliers may maintain the product.
- Demand is smaller.
- Liquid products require specialized manufacturing and packaging.
- Pharmacy inventories may be thinner.
- Shortages or discontinuations can produce temporary price increases.
The branded product may retain a small share among patients or prescribers who prefer continuity, but brand retention is difficult to defend without patent protection or strong contracting leverage.
How strong is the Felbatol patent estate?
The patent estate is weak from a commercial exclusivity perspective because the product is a 30-year-old small molecule with established generic competition.
What formulations are protected by Felbatol patents?
There is no publicly prominent active formulation-patent strategy protecting Felbatol tablets or oral suspension. Any historical formulation rights would not appear to prevent generic access to the core dosage forms.
A company seeking to extend commercial protection would need to rely on a new formulation, delivery system, combination product, or clinically differentiated indication. Such a strategy would require new development and would face a difficult risk-benefit assessment because the active ingredient itself carries serious safety warnings.
Do method-of-use patents protect Felbatol?
No current method-of-use patent strategy appears to materially control felbamate prescribing. The approved uses are established, and generic labels support the core seizure indications.
Potential future use patents would face practical limits. A new indication would need credible clinical differentiation, a defensible patent position, and a population large enough to support development and commercialization.
What market dynamics affect Felbatol demand?
Felbatol demand is structurally limited by the drug's position in the treatment pathway.
How does refractory epilepsy affect demand?
Felbatol is generally reserved for patients whose seizures are inadequately controlled by other treatments or who have specific clinical needs associated with Lennox-Gastaut syndrome. This creates a small but relatively persistent demand base.
Demand is supported by:
- Chronic treatment duration.
- Severe disease burden.
- Limited substitutes for some refractory patients.
- Specialist familiarity with the medicine.
- Need for liquid therapy in selected pediatric patients.
Demand is constrained by:
- Serious hematologic and hepatic risks.
- Monitoring requirements.
- Availability of newer antiseizure medicines.
- Physician reluctance to initiate therapy.
- Patient switching to alternatives with more favorable safety profiles.
The product therefore has low volume but can have high clinical switching costs for individual patients who respond adequately and tolerate treatment.
How does Felbatol compare with newer epilepsy drugs?
| Factor |
Felbatol |
Newer antiseizure medicines |
| Market age |
Mature, approved in 1993 |
Often launched after 2000 |
| Patent position |
Expired or commercially inactive |
May retain patents or exclusivity |
| Safety perception |
Constrained by boxed warning |
Often more favorable, depending on product |
| Use in refractory epilepsy |
Established niche |
Broadening depending on indication |
| Price |
Generic pressure |
Brand pricing often higher |
| Monitoring burden |
Significant |
Varies by drug |
| Commercial growth |
Low |
Can be higher in differentiated indications |
| Biosimilar risk |
None |
None for small molecules; relevant only to biologics |
Felbatol competes less on price than on whether a specialist believes its efficacy justifies the safety-monitoring burden.
What is the financial trajectory for Felbatol?
Felbatol's financial trajectory is best characterized as mature, low-growth, and supply-sensitive.
Public company filings do not generally disclose standalone Felbatol revenue. Where a manufacturer reports a portfolio of generic or specialty products, Felbatol revenue is usually aggregated with other products. This prevents reliable calculation of:
- Annual Felbatol net sales.
- Product-level gross margin.
- Market share by manufacturer.
- Brand versus generic revenue.
- Revenue growth by dosage form.
- Regional sales contribution.
What drives revenue?
Felbatol revenue depends on prescription volume, generic market structure, dosage-form mix, and supply continuity. A simplified commercial model is:
Revenue = treated patients x annual units per patient x realized price
For a mature product, patient volume is likely more stable than price. Generic competition places downward pressure on realized price, while interruptions in supply can temporarily increase prices but reduce reliable revenue and damage customer relationships.
What is the revenue exposure?
The product is unlikely to represent material revenue exposure for a diversified pharmaceutical company unless the company has a concentrated specialty or generic portfolio. Its strategic value may be higher than its revenue value in situations involving:
- A niche epilepsy franchise.
- A hospital or specialty-pharmacy portfolio.
- A manufacturer with underused oral-liquid capacity.
- A distributor seeking supply continuity.
- A portfolio acquisition focused on mature, cash-generating products.
The product's risk-adjusted value is reduced by the boxed warning, generic competition, and lack of patent protection.
What manufacturing and intellectual-property barriers affect Felbatol?
Manufacturing barriers are more important than intellectual-property barriers.
What supply risks affect felbamate?
The market can be vulnerable to supply disruption when only a small number of suppliers maintain commercial production. Key risks include:
- Active pharmaceutical ingredient qualification.
- Batch failure or production-site interruption.
- Specialized oral-suspension manufacturing.
- Packaging and stability requirements.
- Low-volume economics.
- Delayed regulatory remediation.
- Wholesaler inventory concentration.
For tablets, additional suppliers may be able to enter if economics justify regulatory filing and production. For oral suspension, entry may be slower because the addressable market is smaller and manufacturing complexity is higher.
Does felbamate have manufacturing exclusivity?
No. The principal barrier is not an exclusive manufacturing right but the commercial cost of maintaining a reliable product at low volume. A generic manufacturer can face a rational decision to discontinue a low-margin product even when demand remains clinically important.
What patent litigation affects Felbatol?
No major current patent litigation is publicly associated with Felbatol as a commercial driver. The product's litigation profile is materially different from a newly approved branded drug:
- No central active composition-of-matter dispute.
- No major Paragraph IV litigation expected to determine market entry.
- No known settlement structure controlling a future generic launch.
- No biosimilar litigation.
- No evident patent-based launch blockade.
Any transaction involving Felbatol should focus on product liability, pharmacovigilance, supply agreements, manufacturing quality, and regulatory compliance rather than patent litigation.
What licensing deals involve Felbatol?
Felbatol has no widely reported current licensing transaction that defines its market position. Historical commercialization may have involved rights transfers, distributors, or product acquisitions, but these arrangements do not create current exclusivity.
A license covering Felbatol would be commercially meaningful only if it included one or more of the following:
- An exclusive geographic territory.
- A differentiated formulation.
- A supply commitment.
- A specialty-pharmacy channel.
- A branded generic strategy.
- Rights to a new indication.
Absent those elements, a Felbatol license would likely be a mature-product supply or distribution arrangement rather than an innovation-based licensing deal.
What generic launch scenarios exist for Felbatol?
Because generic products are already present, future scenarios involve market reshaping rather than initial entry.
Scenario 1: Stable multi-source supply
Several manufacturers remain active, prices stay competitive, and Felbatol continues as a small specialty generic. This is the base-case commercial outcome.
Scenario 2: Supplier consolidation
One or more manufacturers exit because of low margins. Remaining suppliers gain volume and pricing power, but pharmacies face greater shortage risk.
Scenario 3: Oral-suspension disruption
Tablet supply remains available while suspension supply becomes constrained. Pediatric and dysphagia patients face the highest exposure.
Scenario 4: Brand persistence in a niche
The brand retains limited demand among stable patients or specialty prescribers. This scenario depends on availability, reimbursement, and physician preference rather than patent protection.
Scenario 5: Clinical substitution
Prescribers increasingly use newer antiseizure medicines, reducing felbamate initiation and gradually shrinking the treated population. Existing long-term responders preserve a residual base.
What is the geographic coverage of Felbatol?
Felbamate's commercial relevance is primarily tied to markets with established regulatory approval and epilepsy-specialist prescribing. The United States is the most important reference market because Felbatol has an FDA-approved label and a well-defined boxed-warning framework.
International availability can differ because:
- Felbamate may be marketed under different brand names.
- Regulatory approvals may not mirror the FDA indications.
- Generic registration may vary by country.
- Safety warnings may restrict use more heavily in some jurisdictions.
- Reimbursement and specialist access differ.
The United States remains the clearest market for patent, regulatory, and generic-entry analysis.
Key Takeaways
- Felbatol is felbamate, an FDA-approved antiseizure medicine first approved in 1993.
- Its main uses are refractory partial seizures and Lennox-Gastaut syndrome.
- A boxed warning for aplastic anemia and hepatic failure limits prescribing.
- Patent exclusivity is no longer a meaningful commercial barrier.
- Generic competition is established; future risk centers on supplier consolidation and shortages.
- The oral suspension may have greater supply vulnerability than tablets because of lower volume and manufacturing complexity.
- No material current Paragraph IV campaign, biosimilar risk, or patent litigation is associated with the product.
- Public filings do not provide reliable standalone Felbatol revenue.
- The financial profile is mature, low-growth, and sensitive to price erosion and manufacturing continuity.
- Felbatol's strategic value is concentrated in clinical continuity for refractory patients, not in patent-protected growth.
Frequently Asked Questions
Is Felbatol still available in the United States?
Yes. Felbatol and generic felbamate remain FDA-approved prescription products, although availability can vary by dosage form, manufacturer, and pharmacy inventory.
Is felbamate a controlled substance?
Felbamate is not generally classified as a federally controlled substance in the United States. It is dispensed by prescription because of its medical risks and monitoring requirements.
Can a generic manufacturer launch felbamate without a patent challenge?
Yes. Because meaningful patent exclusivity has expired, a manufacturer does not generally face the type of active patent barrier associated with a newly approved branded drug. FDA approval through the abbreviated new drug application pathway remains necessary.
Is Felbatol used for Lennox-Gastaut syndrome?
Yes. FDA labeling includes use in children with Lennox-Gastaut syndrome, subject to the product's serious safety warnings and monitoring requirements.[1]
Does Felbatol have biosimilar competition?
No. Felbatol is a small-molecule drug, so the relevant competitors are generic felbamate products rather than biosimilars.
References
-
U.S. Food and Drug Administration. (2020). Felbatol (felbamate) prescribing information. FDA/DailyMed.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.
-
National Library of Medicine. (2024). Felbamate drug information. MedlinePlus.
-
U.S. Food and Drug Administration. (1993). FDA approval history for Felbatol (felbamate). U.S. Department of Health and Human Services.
